Karakus Kagan E, Snell-Bergeon Janet, Mason Emma, Akturk Halis K
Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO, USA.
J Diabetes Sci Technol. 2024 Dec 5:19322968241301429. doi: 10.1177/19322968241301429.
Extended hypoglycemia (Ehypo) and extended hyperglycemia (Ehyper) are recently defined continuous glucose monitoring (CGM) metrics by the International Consensus for clinical trials as secondary endpoints for continuous outcomes. This study aims to evaluate the changes in Ehypo and Ehyper before and after automated insulin delivery (AID) initiation in adults with type 1 diabetes (T1D).
This is a retrospective single-center study that evaluated Ehypo and Ehyper in addition to other CGM metrics in 154 adults that initiated an AID system. Metrics were compared before and after AID initiation by Wilcoxon signed-rank test.
Median (interquartile range) Ehypo (<70 mg/dL) events/week decreased from 0.1 (0-0.4) to 0 (0-0.1) and Ehyper (>250 mg/dL) events/week decreased from 2.2 (0.9-4.5) to 0.8 (0.3-1.7) (both < .001) after AID initiation compared with before AID initiation. All other CGM metrics improved after AID initiation. There was a strong positive correlation between Ehyper (>250 mg/dL) and mean glucose (before AID: = 0.947, after AID: = 0.894), glucose management indicator (before AID: = 0.947, after AID: = 0.887), and time above range (TAR; >180 mg/dL) (before AID: = 0.957, after AID: = 0.917) and a strong positive correlation between Ehypo (<70 mg/dL) and time below range (TBR; <70 mg/dL) (before AID: = 0.823, after AID: = 0.608) before and after AID initiation, respectively.
Automated insulin delivery initiation significantly improved Ehypo and Ehyper metrics. Ehypo and Ehyper had a strong positive correlation with TBR and TAR, respectively. Ehypo and Ehyper events can be used in addition to TBR and TAR metrics in clinical studies as secondary outcomes.
近期,国际临床试验共识将延长性低血糖(Ehypo)和延长性高血糖(Ehyper)定义为连续血糖监测(CGM)指标,作为连续性结果的次要终点。本研究旨在评估1型糖尿病(T1D)成人患者开始自动胰岛素给药(AID)前后Ehypo和Ehyper的变化。
这是一项回顾性单中心研究,除了评估154例开始使用AID系统的成人患者的其他CGM指标外,还评估了Ehypo和Ehyper。通过Wilcoxon符号秩检验比较AID开始前后的指标。
与AID开始前相比,AID开始后,Ehypo(<70 mg/dL)事件/周的中位数(四分位间距)从0.1(0 - 0.4)降至0(0 - 0.1),Ehyper(>250 mg/dL)事件/周从2.2(0.9 - 4.5)降至0.8(0.3 - 1.7)(两者均P <.001)。AID开始后所有其他CGM指标均有所改善。Ehyper(>250 mg/dL)与平均血糖(AID开始前:r = 0.947,AID开始后:r = 0.894)、血糖管理指标(AID开始前:r = 0.947,AID开始后:r = 0.887)以及高于范围时间(TAR;>180 mg/dL)(AID开始前:r = 0.957,AID开始后:r = 0.917)之间存在强正相关,Ehypo(<70 mg/dL)与低于范围时间(TBR;<70 mg/dL)(AID开始前:r = 0.823,AID开始后:r = 0.608)之间在AID开始前后分别存在强正相关。
开始自动胰岛素给药显著改善了Ehypo和Ehyper指标。Ehypo和Ehyper分别与TBR和TAR有强正相关。在临床研究中,除了TBR和TAR指标外,Ehypo和Ehyper事件可用作次要结局。